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M
ost countries in Europe 
and North America target 
influenza immunization 
to persons at highest risk for 
complications, including seniors 65 
years and older, those with certain 
chronic illnesses, and young children. 
Despite increases in vaccination rates in 
these high-risk groups over the last few 
decades, morbidity and mortality from 
influenza remain high. 
Disappointing Results of Targeted 
Influenza Vaccination Strategies
Seniors suffer about 90% of the 
influenza seasonal mortality burden, 
and rates of hospitalization and death 
are increasing as the population ages 
[1]. Studies of national trends in the 
United States and Italy showed that even 
after adjusting for population aging and 
pathogenicity of circulating influenza 
viruses, vaccine uptake in seniors 
was not associated with a decline in 
influenza-related mortality ([2,3]; Figure 
1). These disappointing experiences can 
be explained by the phenomenon of 
immune senescence, whereby immune 
response to vaccines declines in the last 
decades of life [4]. These results—along 
with a growing understanding that the 
expected effectiveness of vaccination 
had been greatly overestimated in 
seniors [5,6]—have fueled debate over 
the best strategy to protect high-risk 
populations [1,7]. 
In response, the US public health 
authorities have gradually broadened 
the recommended target group for 
vaccination, which now includes 
all children aged six months to 18 
years of age [8]. This new strategy 
is likely to reduce severe pediatric 
influenza outcomes, and it could also 
protect seniors by reducing influenza 
transmission from high-transmitter 
populations, although the exact 
benefits have yet to be evaluated. 
Evaluation of the Universal 
Vaccination Program in Ontario
The Ontario province of Canada 
launched a unique influenza vaccination 
campaign in October 2000, offering 
free influenza vaccine to everyone over 
six months of age through extensive 
delivery in nontraditional settings, 
including community centers and 
shopping malls. In this issue of PLoS 
Medicine, Kwong and colleagues report 
their evaluation of the impact of this 
intense and costly strategy on a variety 
of influenza-related outcomes [9]. The 
authors compared changes in influenza 
burden in Ontario before (1997–2000) 
and after (2000–2004) universal 
vaccination was implemented—
relative to changes in surrounding 
Canadian provinces that had lower 
vaccine uptake. Electronic health 
databases and influenza laboratory 
surveillance data were used to estimate 
trends in influenza-related mortality, 
hospitalization, and visits to emergency 
departments and doctors’ offices. 
Study Results
The authors found that the influenza 
burden decreased as vaccination rates 
increased across all age groups in 
Ontario, with a 49%–59% decline for 
various outcomes (p < 0.002), relative 
to other provinces. Comparisons 
across provinces showed that there was 
also a convincing coverage–response 
relationship among people under 
65 years, in that the largest vaccine 
uptakes corresponded to the greatest 
reductions in disease burden.
However, the results were more 
confusing for seniors 65 years and 
older. Surprisingly, the largest 
reductions in disease burden in seniors 
were observed in provinces with the 
lowest vaccine uptakes in this age group. 
This counterintuitive relationship 
suggests that changes in vaccine uptake 
in seniors cannot explain the observed 
burden reduction in this age group. 
Further, some of the sensitivity analyses 
revealed additional unexpected 
results, including an attenuation of 
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Linked Research Article
This Perspective discusses the 
following new studies published in PLoS
Medicine:
Kwong JC, Stukel TA, Lim J, McGeer 
AJ, Upshur REG, et al. (2008) The effect 
of universal influenza immunization 
on mortality and health care use. PLoS 
Med 5(10): e211. doi:10.1371/journal.
pmed.0050211
Comparing influenza-related mortality 
and health care use between Ontario 
and other Canadian provinces, Jeffrey 
Kwong and colleagues find evidence that 
Ontario’s universal vaccination program 
has reduced the burden of influenza.
van den Dool C, Bonten MJM, Hak E, 
Heijne JCM, Wallinga J (2008) The effects 
of influenza vaccination of health care 
workers in nursing homes: Insights from 
a mathematical model. PLoS Med 5(10): 
e200. doi:10.1371/journal.pmed.0050200
Using a mathematical model to 
simulate influenza transmission in 
nursing homes, Carline van den Dool and 
colleagues find that each additional staff 
member vaccinated further reduces the 
risk to patients.PLoS Medicine  |  www.plosmedicine.org 1424 October 2008  |  Volume 5  |  Issue 10  |  e216
vaccination benefits when focusing 
on severe influenza seasons or using 
more data years. In general, however, 
most sensitivity analyses confirmed the 
health benefits of the Ontario strategy 
in all age data, although the age 
discrepancies were not resolved.
Strengths and Limitations
Influenza disease burden must be 
inferred indirectly through statistical 
methods ([1]; Figure 1), in the face of 
substantial interannual variations in 
pathogenicity of circulating influenza 
viruses, vaccine mismatch seasons, 
and geographical variability. Thus 
Kwong and colleagues [9] met great 
challenges to evaluate the effect of 
Ontario’s population-level experiment. 
By comparing trends between Ontario 
and other Canadian provinces and 
conducting extremely thorough 
sensitivity analyses, the authors cleverly 
attempted to control for factors 
unrelated to vaccine uptake. But even 
so, lack of statistical power is a key 
limitation of observational studies 
comparing disease trends across time 
periods and geographical regions with 
different intervention strategies. 
To illustrate this methodological 
problem, if we apply the same approach 
to US data, we observe large reductions 
in influenza-related hospitalization 
and deaths before and after the year 
2000 in persons 65 years and older, of 
similar magnitude to those found in 
Ontario (Table 1). However, vaccine 
coverage in US seniors has remained 
stable in this period ([10]; Figure 1), 
illustrating that trend analyses need 
to be interpreted with caution when 
the study period is short. By contrast, 
comparison of vaccination and disease 
trends in people 50–64 years old 
suggests that larger burden reductions 
are found in Ontario than in the US, 
paralleling a larger increase in vaccine 
uptake in this age group in Ontario. 
This is an appealing finding, given 
that numerous randomized clinical 
trials have reported 70%–90% vaccine 
efficacy against laboratory-confirmed 
influenza in younger adults.
A second modeling study presented 
in this issue of PLoS Medicine [11]
highlights similar methodological 
problems in the evaluation of 
vaccination strategies, and provides 
insights into the benefits of vaccinating 
health care workers to protect nursing 
home residents. Computational 
simulations of this indirect strategy 
suggest that, even though increasing 
the proportion of vaccinated health 
care workers reduces the risk to 
nursing home residents, even 100% 
vaccination coverage cannot entirely 
eliminate influenza transmission 
in nursing homes. Further, these 
simulations reveal that discordances 
in results of previous clinical studies 
can be reconciled by taking into 
account the effects of small sample size 
and heterogeneity in study settings. 
In summary, both studies [9,11] 
illustrate how difficult it is to evaluate 
the benefits of influenza vaccination 
strategies, especially in observational 
settings.
The Way Forward
Based on the experience in Ontario 
[9] and elsewhere, there is now 
solid evidence for the effectiveness 
of influenza vaccination in people 
under 65 years. However, the direct 
and indirect benefits of universal 
immunization remain unclear for 
seniors, and Kwong and colleagues’ 
study [9] was likely underpowered to 
evaluate such benefits. 
Cluster-randomized trials have been 
proposed as an alternative and more 
powerful design than observational 
studies for evaluating the indirect 
effects of influenza immunization 
strategies [12]. The increasing pressure 
doi:10.1371/journal.pmed.0050216.g001
Figure 1. Time Trends in Influenza Vaccine Coverage and Influenza-Related Mortality in 
People 65 Years and Older in the US, Based on Two Death Categories
(A) All-cause mortality. (B) Pneumonia and influenza mortality. The black curve illustrates observed 
monthly mortality rates, the purple curve represents a monthly model baseline above which 
mortality is attributed to influenza [1], and the green curve represents trends in seasonal vaccine 
coverage in people 65 years and older. Red shaded areas represent seasonal estimates of excess 
mortality attributed to influenza (observed over baseline), while blue areas represent non-
influenza mortality. Red stars indicate epidemic seasons dominated by the more severe A/H3N2 
influenza viruses [10]. Grey arrows indicate the two periods used in Kwong et al.’s comparative 
study to evaluate the benefits of universal immunization in Ontario, Canada (1997–2000 and 
2000–2004) [9]. Note the less frequent circulation of severe A/H3N2 viruses in the second part of 
Kwong et al.’s study period, 2000–2004. Trends in influenza burden estimates for these periods are 
provided for the US and Ontario in Table 1.PLoS Medicine  |  www.plosmedicine.org 1425 October 2008  |  Volume 5  |  Issue 10  |  e216
to improve influenza control may 
eventually generate sufficient interest 
in sponsoring such large-scale and 
costly randomized studies. Ironically, 
there is only a short time window of 
opportunity for these studies—once 
pediatric or universal vaccination policy 
becomes established, there is no ethical 
“control” community left. 
In the meantime, the Ontario 
intervention program provides valuable 
information on the benefits of large-
scale immunization efforts, and more 
precise estimates of the direct and 
indirect benefits in different age 
groups will likely become available 
over time. Finally, we note that the 
Ontario program was very successful 
in developing innovative channels 
for influenza vaccine delivery—an 
experience extremely useful in the 
context of pandemic preparedness.
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Table 1. Comparison of Trends in Age-Specific Rates of Influenza-Related Mortality, Hospitalization, and Vaccine Coverage 
Between Two Periods (1997–2000 and 2000–2004) in the US and Ontario, Canada
Setting Age Group 
(Years)
Percentage Increase in Vaccine Coverage 
Between the Two Periods (Mean Vaccine 
Coverage Before and After 2000)
Percentage Decrease in 
Influenza-Related Mortalitya
Between the Two Periods
Percentage Decrease in Influenza-
Related Hospitalizationsb Between 
the Two Periods
Ontario,
Canadac
50–64 +26% (21%; 47%) 66%d 92%
≥65 +14% (61%; 75%) 75%–78%e 67%–83%e
USf 50–64 +5% (35%; 40%)g 50% 78%
≥65 +3% (64%; 67%)g 56%–57%e 69%–77%e
See Figure 1 for exact definition of seasons included. All estimates are statistically different from 0, except when otherwise noted.
aBased on excess all-cause deaths. Similar estimates are obtained from a more specific outcome in the US, such as excess pneumonia and influenza mortality (Figure 1).
bBased on excess pneumonia and influenza hospitalizations.
cOntario data derived from [9].
dThis estimate is not statistically different from 0.
eRange of estimates in 3 senior age groups: 65–74, 75–84, and 85 years and over.
fUS estimates derived from a seasonal regression model applied to national data as in [3] (see also Figure 1).
gUS coverage data derived from [10].
doi:10.1371/journal.pmed.0050216.t001